 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for November 21, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| TIIAY KKR | Hot Stocks20:18 EST Telecom Italia board met to assess non binding indication of interest by KKR - Telecom Italia (TIIAY) stated: "TIM's board of directors met today under the chairmanship of Salvatore Rossi, and acknowledged the intention of Kohlberg Kravis Roberts & Co. L.P., or 'KKR,' to date qualified as "non-binding and indicative", to launch a possible public tender offer for the entire share capital of the company, both ordinary and savings shares, aimed at the delisting of the company. The indication of interest, which is non-binding - as specified above - and based on publicly available information, would be conditional upon a minimum level of acceptance of 51% for both classes of shares. The indication of interest was qualified by KKR as 'friendly' and aims at obtaining approval by TIM's directors and support by the company's management. For the time being, it is conditional - among others - to an estimated four-week confirmatory due diligence, as well as clearance by key government stakeholders, as TIM is subject to the Government's special powers, so called Golden Power. The indication of interest foresees a price, to be considered, for the time being, indicative only as well as non-binding, to be paid fully in cash, equal to Euro 0.505 per ordinary and/or savings share." Reference Link
|
| MNST... | Hot Stocks20:06 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Monster Beverage (MNST), the maker of energy drinks, is exploring a combination with Corona brewer Constellation Brands (STZ), Bloomberg's Ed Hammond reported, citing people familiar with the matter. Monster Beverage, which has Coca-Cola (KO) as a major shareholder, has discussed a potential deal with advisers, the people said. 2. KKR (KKR) offered to buy Telecom Italia SpA (TIIAY) for $12.2B, seeking to tempt investors including Vivendi SE (VIVHY) with a healthy premium after the company lost about half its market value in the past five years, Bloomberg's Daniele Lepido reported. "The board acknowledged the intention of KKR to launch a possible public tender for the entire share capital of the company," the board said in a statement Sunday after meeting to consider the proposal, which currently is "non-binding and indicative." 3. As supply-chain issues roil the tech sector, no company underscores the issue more than Cisco Systems, Eric J. Savitz wrote in this week's edition of Barron's. The stock fell more than 6% on Thursday after the company reported financial results that were dented by a panoply of component delays. And yet, it's hard to find an enterprise tech company with a more appealing long-term outlook, the author contended. While there will be continued near-term noise for Cisco (CSCO), investors should hop aboard now-the selloff this past week has made a cheap stock even cheaper, the publication added. 4. Sony's (SONY) "Ghostbusters: Afterlife" easily won this weekend's domestic box office with a better-than-expected $44M from 4,315 locations. Overseas, the direct sequel to the 1984 original "Ghostbusters" earned $16M from 31 markets for a worldwide total of $60M. 5. Dominion Energy (D), LCI Industries (LCII), Macy's (M), Coterra Energy (CTRA), Power & Digital Infrastructure Acquisition (XPDI), Marathon Digital (MARA), and Rio Blockchain (RIOT) saw positive mentions in this week's edition of Barron's.
|
| UBS | Hot Stocks19:52 EST UBS Board of Directors announces Chairman, Vice Chairman nominations - The Board of Directors of UBS Group AG will nominate Colm Kelleher as new Chairman and Lukas Gahwiler as Vice Chairman for election to the Board at the Annual General Meeting on 6 April 2022. If elected, Colm Kelleher will succeed Axel A. Weber, who will have reached the maximum term limit after ten years in office and will thus not stand for re-election. Jeremy Anderson will continue in his role as Senior Independent Director and non-executive member of the Board.
|
| XNCR | Hot Stocks18:35 EST Zenas BioPharma acquires exclusive worldwide rights to obexelimab from Xencor - Xencor and Zenas BioPharma announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab. Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain and uses Xencor's XmAb(R) Immune Inhibitor Fc Domain to target FcgammaRIIb, a receptor that inhibits the function of B-cells, which are important components in the immune system. Xencor demonstrated through early-stage clinical studies that obexelimab effectively inhibits B-cell function without depleting the cells and generates an encouraging treatment effect in patients with multiple autoimmune diseases. Under the terms of the new agreement, Zenas will issue to Xencor a warrant giving Xencor the right to acquire additional Zenas equity, such that Xencor's total equity in Zenas would be 15% of its fully diluted capitalization following the closing of Zenas' next round of equity financing, subject to certain requirements. Xencor previously received equity in Zenas under a separate license agreement. Xencor is also eligible to receive up to $480 million based on the achievement of certain clinical development, regulatory and commercialization milestones and is eligible to receive tiered, mid-single digit to mid-teen percent royalties upon commercialization of obexelimab, dependent on geography. Zenas will have sole responsibility for advancing the research, development, regulatory and commercial activities of obexelimab worldwide.
|
| PBYI | Hot Stocks15:10 EST Puma Biotechnology presents data from Neratinib arm of INSIGhT trial - Puma Biotechnology announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of Innovative Glioblastoma Therapy at the 2021 Society for Neuro-Oncology Annual Meeting. The INSIGhT trial is a multisite investigator-initiated Phase II screening adaptive platform trial where patients with newly diagnosed unmethylated glioblastoma who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. All patients receive radiation therapy and temozolomide and then patients are randomized to receive either adjuvant temozolomide or adjuvant treatment with an experimental agent. At the initiation of INSIGhT, three experimental arms, each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms were allowed to drop because of low probability of treatment impact on overall survival. The primary endpoint of INSIGhT is overall survival. Progression-free survival analysis is used to influence randomization. For the neratinib arm of the trial, patients received 240 mg of neratinib daily as a single agent with mandatory loperamide prophylaxis. For the neratinib arm of the trial, there were 149 patients in the intent-to-treat population, including 81 patients treated with neratinib and 68 patients in the control arm. For the intent-to-treat population, PFS was not significantly longer with neratinib versus the control arm and there was no significant improvement in OS between neratinib versus the control arm. For patients with activation of the EGFR pathway, defined as patients with either EGFR amplification or mutation, PFS was significantly longer with neratinib versus the control arm; however, there was no significant improvement in overall survival between neratinib versus the control arm. Neratinib was generally well tolerated in the trial and toxicities for neratinib were similar to that previously described. For the 81 patients treated with neratinib, there were 6 cases of grade 3 diarrhea and no cases of grade 4 diarrhea. No new toxicity signals were identified in the trial.
|
| EXEL | Hot Stocks15:05 EST Exelixis announces detailed results from Phase 3 COSMIC-312 trial - Exelixis announced detailed results from the first planned analysis of COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. At a median follow-up of 15.8 months, the primary analysis showed the primary endpoint of progression-free survival per RECIST 1.1 by blinded independent review committee was met; in the PFS intent-to-treat population, cabozantinib in combination with atezolizumab significantly reduced the risk of disease progression or death by 37% compared with sorafenib. Median PFS was 6.8 months for cabozantinib in combination with atezolizumab versus 4.2 months for sorafenib. New results presented during the 2021 ESMO Virtual Plenary include detailed data for a prespecified interim analysis for the primary endpoint of overall survival in the intent-to-treat population, which was conducted at the same time as the primary analysis for PFS in the PITT population. At a median follow-up of 13.6 months, the interim OS analysis in the ITT population showed a trend that favored cabozantinib in combination with atezolizumab but did not reach statistical significance. Median OS was 15.4 months for cabozantinib in combination with atezolizumab versus 15.5 months for sorafenib. The trial is continuing as planned to the final analysis of OS, anticipated in early 2022. Objective response rates per RECIST 1.1 by BIRC in the ITT population were 11% for cabozantinib in combination with atezolizumab, 3.7% for sorafenib and 6.4% for cabozantinib monotherapy. Disease control rates - complete response + partial response + stable disease - were 78%, 65% and 84%, respectively. The safety profile for cabozantinib in combination with atezolizumab was consistent with those previously observed for each single agent, and no new safety signals were identified. The most common grade 3 or higher adverse events for cabozantinib in combination with atezolizumab were palmar-plantar erythrodysesthesia, hypertension, aspartate aminotransferase increased and alanine aminotransferase increased. Rates of grade 3/4 treatment-related AEs were 51% for cabozantinib and atezolizumab, 30% for sorafenib and 52% for cabozantinib monotherapy. Rates of grade 5 treatment-related AEs were 1.9% for cabozantinib and atezolizumab, 0.5% for sorafenib and 0.5% for cabozantinib monotherapy. Treatment discontinuations due to treatment-related AEs in the combination arm were 6.1% for the combination of cabozantinib and atezolizumab and 14.0% for either cabozantinib and/or atezolizumab. The treatment-related discontinuation rate for sorafenib was 7.7% and for cabozantinib monotherapy was 8.5%.
|
